Gemtuzumab ozogamicin, as the first ADCs approved by the FDA, was indicated for the treatment of first-relapsed acute myeloid leukemia (AML) in patients aged 60 years or older who are CD33 positive and unsuitable for cytotoxic chemotherapy (19). This evidence concerns the gene CD33 and acute myeloid leukemia.